BÜHLMANN Quantum Blue® fCAL Citation:
Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease, Can J Gastroenterol Hepatol. 2016, PMID: 27774443.
Highlight from this publication: “Given the noninvasive nature, quick turnaround of FCAL test, and good correlation with endoscopy in colonic inflammatory bowel diseases as we have shown in this study, FCAL can help in monitoring disease activity and maybe used as a tool along with other serologic and clinical measures to guide further investigation and therapy.”
This Canadian study represents how fCAL testing is utilized in the field for monitoring disease activity in IBD. The reference for the cut-off value (250 ug/g) was based on guidance described in a very comprehensive review by Mao et al. (2012), focused upon investigation and prediction of relapse in quiescent IBD subjects.